JP7519359B2 - レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法 - Google Patents

レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法 Download PDF

Info

Publication number
JP7519359B2
JP7519359B2 JP2021536077A JP2021536077A JP7519359B2 JP 7519359 B2 JP7519359 B2 JP 7519359B2 JP 2021536077 A JP2021536077 A JP 2021536077A JP 2021536077 A JP2021536077 A JP 2021536077A JP 7519359 B2 JP7519359 B2 JP 7519359B2
Authority
JP
Japan
Prior art keywords
aav
rtx
vehicle
mice
gait
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514695A (ja
JP2022514695A5 (https=
Inventor
アレクシス ナハマ，
ヘンリー ホンジュン ジ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2022514695A publication Critical patent/JP2022514695A/ja
Publication of JP2022514695A5 publication Critical patent/JP2022514695A5/ja
Application granted granted Critical
Publication of JP7519359B2 publication Critical patent/JP7519359B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021536077A 2018-12-24 2019-12-23 レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法 Active JP7519359B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784650P 2018-12-24 2018-12-24
US62/784,650 2018-12-24
US201962914170P 2019-10-11 2019-10-11
US62/914,170 2019-10-11
PCT/US2019/068235 WO2020139797A1 (en) 2018-12-24 2019-12-23 Methods for treating parkinson's disease by administering resiniferatoxin

Publications (3)

Publication Number Publication Date
JP2022514695A JP2022514695A (ja) 2022-02-14
JP2022514695A5 JP2022514695A5 (https=) 2023-01-05
JP7519359B2 true JP7519359B2 (ja) 2024-07-19

Family

ID=71126251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536077A Active JP7519359B2 (ja) 2018-12-24 2019-12-23 レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法

Country Status (8)

Country Link
US (1) US12201608B2 (https=)
EP (1) EP3902539B1 (https=)
JP (1) JP7519359B2 (https=)
KR (1) KR20210107086A (https=)
CN (1) CN113473983B (https=)
AU (1) AU2019414329A1 (https=)
CA (1) CA3124499A1 (https=)
WO (1) WO2020139797A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108979A (ko) 2018-12-21 2021-09-03 소렌토 쎄라퓨틱스, 인코포레이티드 부적응 통증을 치료하기 위한 레시니페라톡신의 신경 주위 투여
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
JP7530365B2 (ja) 2019-01-22 2024-08-07 ソレント・セラピューティクス・インコーポレイテッド レシニフェラトキシンを投与することによって変形性関節症疼痛を処置するための方法
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010280668A (ja) 2002-12-18 2010-12-16 Alcion Therapeutics Inc カプサイシノイドの投与
JP2013056893A (ja) 2007-11-19 2013-03-28 Nestec Sa 口腔咽頭嚥下障害の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
WO2008109026A1 (en) 2007-03-05 2008-09-12 Mt Cook Pharma Pharmaceutical compositions for the localized treatment of neurogenic dysfunction
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN105017155B (zh) * 2014-04-16 2017-06-16 华东师范大学 类三环二萜并吡唑衍生物及其制备方法和应用
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
CN107126445A (zh) * 2017-04-20 2017-09-05 江南大学 粪菌移植在治疗帕金森病方面的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010280668A (ja) 2002-12-18 2010-12-16 Alcion Therapeutics Inc カプサイシノイドの投与
JP2013056893A (ja) 2007-11-19 2013-03-28 Nestec Sa 口腔咽頭嚥下障害の治療

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dorothy Cimino Brown，Pharmaceuticals，2016年，9, 47，p.1-11，doi:10.3390/ph9030047
Jin H. Nam et al.，BRAIN，2015年，138，p.3610-3622
Young C Chung et al.，Experimental & Molecular Medicine，2017年，49, e298，p.1-9
ZhenXiang Zhao et al.，Neurochemical Research，2017年，Vol.42，p.3431-3438

Also Published As

Publication number Publication date
JP2022514695A (ja) 2022-02-14
US20210299090A1 (en) 2021-09-30
CA3124499A1 (en) 2020-07-02
EP3902539B1 (en) 2024-07-31
CN113473983A (zh) 2021-10-01
EP3902539A4 (en) 2022-08-24
WO2020139797A1 (en) 2020-07-02
KR20210107086A (ko) 2021-08-31
EP3902539A1 (en) 2021-11-03
AU2019414329A1 (en) 2021-06-10
CN113473983B (zh) 2024-07-23
US12201608B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
JP7519359B2 (ja) レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法
US8946151B2 (en) Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
CA2761156C (en) Methods of preventing ischemic injury using peripheral nociceptive stimulation
EA030478B1 (ru) Применение биотина для лечения рассеянного склероза
Niu et al. Effect of bilateral deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease
US12084491B2 (en) Treatment of Parkinson's disease
WO2016061190A1 (en) Method for treating neurodegenerative diseases
Godinho et al. Stereotactic lesion in the forel's field H: a 2-Years prospective open-label study on motor and nonmotor symptoms, neuropsychological functions, and quality of life in parkinson disease
US20040209810A1 (en) Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
Hosseini et al. Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis
Chang et al. Combined bilateral anterior cingulotomy and ventral capsule/ventral striatum deep brain stimulation for refractory obsessive-compulsive disorder with major depression: do combined procedures have a long-term benefit?
Fotuhi et al. The effects of obesity on brain structure and size
US8633165B2 (en) Neuroprotective effects of 2DG in traumatic brain injury
JP2008501774A (ja) グリア細胞株由来神経栄養因子の不確帯への直接注入による、ヒトのパーキンソン病の治療方法
EP4615451A1 (en) Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
GB2595077A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
US11446264B2 (en) Memory manipulation via modification of protein kinase C zeta activity
US10285935B2 (en) Non-invasive method for direct delivery of therapeutics to the spinal cord in the treatment of spinal cord pathology
US20200016145A1 (en) Treatment of chronic traumatic encephalopathy
KR20220029740A (ko) 발작을 치료하고 그의 진행을 억제하는 방법
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240708

R150 Certificate of patent or registration of utility model

Ref document number: 7519359

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150